CDX-301

Trials studying CDX-301

• phase1CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancerrecruitingn=30
• phase2FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancercompletedn=33
• phase1NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanomaactive not recruitingn=10
• phase2Converting HR+ Breast Cancer Into an Individualized Vaccinerecruitingn=100
• phase2Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patientsterminatedn=16
• phase1Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinationscompletedn=43
• phase1A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignanciescompletedn=132
• phase2FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapyterminatedn=5